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IntroductIon
Group 2 innate lymphoid cells (ILC-2s) lack antigen-specific 
receptors and primarily render their function via cytokine 
signaling (Bartemes et al., 2012; Spits and Cupedo, 2012; 
Huang et al., 2015). ILC-2s were initially described by several 
groups and designated as natural helper cells (Koyasu et al., 
2010; Moro et al., 2010), nuocytes (Neill et al., 2010; Bar-
low et al., 2012, 2013), or innate helper 2 cells (Price et al., 
2010) that respond to tissue-derived signals including IL-25, 
IL-33 and thymic stromal lymphopoietin (TSLP). ILC-2s 
express IL-33 receptor (ST2), IL-25 receptor (IL-17RB), 
KLRG1 and naturally reside in tissue sites such as the lung, 
small intestine, skin and adipose tissues. ILC-2s initiate im-
mune responses against parasites (Fallon et al., 2006; Huang et 
al., 2015), participate in inflammatory processes, such as air-
way hyperactivity (Chang et al., 2011), allergen induced lung 
inflammation (Motomura et al., 2014), and allergic atopic 
dermatitis (AD) in humans (Salimi et al., 2013). ILC-2s also 
contribute toward lung tissue repair (Monticelli et al., 2011), 
adipose tissue homeostasis (Brestoff et al., 2015; Lee et al., 
2015), and cutaneous wound healing (Yin et al., 2013; Rak et 
al., 2016). Therefore, elucidating immunoregulatory mecha-
nisms that can modulate ILC-2 cell number and function can 
identify important checkpoints that can be manipulated for 
controlling type 2–mediated immune responses.
Recent studies on ILC-2s in airway inflammation have 
identified a positive regulatory axis driven by ICOS signal-
ing (Maazi et al., 2015; Molofsky et al., 2015; Paclik et al., 
2015). Studies on negative co-receptor mediated regulation 
of ILC-2s has been restricted to the role of KLRG1, which 
has been previously shown to inhibit ILC-2 effector response 
(Salimi et al., 2013). Here, we have investigated the role of 
PD-1 in regulating KLRG1+ ILC-2 subsets and demonstrate 
the downstream signaling mechanism by which PD-1 regu-
lates KLRG1+ILC-2s. PD-1 is related to the CD28 super-
family and is expressed on activated T cells, B cells, monocytes, 
and macrophages. It has two binding partners, namely PDL-1 
(Dong et al., 1999) and PDL-2 (Latchman et al., 2001; Keir et 
al., 2008; Fife et al., 2009). Co-stimulation of PD-1 by either 
of these ligands activate inhibitory signals in T cells which 
either prevent T cell proliferation or render a regulatory phe-
notype to the T cells (Fife et al., 2009; Francisco et al., 2009; 
Amarnath et al., 2010, 2011). These varied immune-tolerant 
signaling cascades occur through SHP1/2 phosphatases, 
which are recruited to the ITIM and ITSM cytoplasmic do-
mains of the PD-1 receptor (Okazaki et al., 2001; Parry et 
al., 2005). The recruited SHP1/2 phosphatases dephosphor-
ylate STATs and/or AKT, thereby dampening T helper cell 
function (Franceschini et al., 2009; Francisco et al., 2009; 
Amarnath et al., 2011). In particular PD-1 can specifically 
inhibit STAT5 signaling in T regulatory cells (Franceschini 
et al., 2009). It is yet to be clarified if such PD-1–mediated 
tolerance mechanisms occur in ILC subsets.
Tumors (Wang and Chen, 2011), viruses (Barber et al., 
2006; Day et al., 2006; Trautmann et al., 2006), and bacteria 
(Das et al., 2006; Beswick et al., 2007; Barber et al., 2011) 
Group 2 innate lymphoid cells (ILc-2s) regulate immune responses to pathogens and maintain tissue homeostasis in response 
to cytokines. Positive regulation of ILc-2s through IcoS has been recently elucidated. We demonstrate here that Pd-1 is an 
important negative regulator of KLrG1+ ILc-2 function in both mice and humans. Increase in KLrG1+ ILc-2 cell numbers was 
attributed to an intrinsic defect in Pd-1 signaling, which resulted in enhanced StAt5 activation. during nippostrongylus 
brasiliensis infection, a significant expansion of KLrG1+ ILc-2 subsets occurred in Pdcd1−/− mice and, upon adoptive transfer, 
Pdcd1−/− KLrG1+ ILc-2s significantly reduced worm burden. Furthermore, blocking Pd-1 with an antibody increased KLrG1+ 
ILc-2 cell number and reduced disease burden. therefore, Pd-1 is required for maintaining the number, and hence function, 
of KLrG1+ ILc-2s.
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manipulate the PD-1 signaling pathway to evade host im-
mune responses. In particular, clinical trials that use PD-1 
blocking antibody have shown phenomenal success in can-
cer immunotherapy (Topalian et al., 2012; Yaqub, 2015). 
Parasitic worms also exploit the PD-1 pathway to create an 
immune-suppressive microenvironment by inducing macro-
phages with suppressor function (Smith et al., 2004; Terrazas 
et al., 2005). Hence, PD-1–mediated tolerance mechanisms in 
adaptive and innate immune cells, with respect to tumors and 
pathogens, have been extensively studied. However, the cel-
lular mechanism by which PD-1 modulates ILC-2 function 
during disease pathogenesis is still largely unknown.
In this study, we have explored whether PD-1 regulates 
ILC-2 cells. We demonstrate that PD-1 is a critical negative 
regulator of KLRG1+ ILC-2 subsets. Disrupting PD-1 sig-
naling either by genetic deletion or by antibody blockade 
significantly enhanced KLRG1+ ILC-2 cells in both number 
and function, thereby efficiently clearing Nippostrongylus 
brasiliensis worms in mice. In humans, we found that PD-1 
is exclusively expressed by ILC-2s (and not ILC-1 or ILC-3) 
and regulates human ILC-2 function.
reSuLtS
Pdcd1−/− mice possess enhanced KLrG1+ ILc-2 subsets
The expression and regulatory function of PD-1 in T cells, 
B cells, and myeloid cells has been previously characterized 
(Agata et al., 1996; Okazaki et al., 2002), but its role in ILCs is 
yet to be defined. Using previously defined gating strategy for 
ILC-2s (Chang et al., 2011; Monticelli et al., 2011; Halim et 
al., 2012), we found that Lin−CD45+CD90+CD25+CD127+ 
KLRG1+ ILC-2s expressed PD-1 in WT mice (Fig. S1, A–C). 
We next explored the functional consequence of PD-1 ex-
pression on KLRG1+ILC-2s by comparing the frequency of 
these subsets in WT and Pdcd1−/− mice. Initial analysis sug-
gested that WT and Pdcd1−/− KLRG1+ILC-2s showed sim-
ilar trend in IL-7R and IL-2R surface expression (Fig. S1, D 
and E). Therefore, we investigated the frequency of ILC-2s in 
WT and Pdcd1−/− mice. In all organs tested, tissue-resident 
Lin−CD45+CD90+CD25+CD127+ ILCs were increased and 
a significant difference was noted in the lungs and skin of 
Pdcd1−/− mice (Fig. 1, A and B). Next, we evaluated if there 
was a difference in ILC-2 subsets between WT and Pdcd1−/− 
mice. A significant increase in KLRG1+ ILC-2s was observed 
in the lungs of Pdcd1−/− mice (Fig. 1 C). Although there was 
a small increase in KLRG1+ ILC-2s in the small intestine 
and skin, a significant statistical difference was not observed 
(Fig. 1 D). We next evaluated if there was a difference in the 
cytokine expression within the KLRG1+ ILC-2s. Although 
both WT and Pdcd1−/− KLRG1+ ILC-2s had similar IL-5 
and IL-13 expression by intracellular flow cytometry (Fig. 1, 
E–G), the cytokine profile of WT KLRG1+ILC-2s that were 
PD-1− or PD-1+ was altered. In the WT ILC-2s, PD-1− pop-
ulation produced higher amounts of effector cytokines such 
as IL-13 compared to the PD-1+ subsets (Fig. 1, H and I). 
These data led us to investigate the kinetics of PD-1 expres-
sion on KLRG1+ILC-2s and their potential function in these 
cells. We found that KLRG1+ILC-2s up-regulated PD-1 ex-
pression in response to IL-2 and IL-7 stimulation. PD-1 ex-
pression was significantly increased in the presence of IL-33 
cytokine, but a similar effect was not noted with IL-25 or 
TSLP (Fig. S1, F and G). Collectively, these data suggest that 
PD-1 expression on ILC-2s is regulated by integrative signals 
from IL-2, IL-7, and IL-33.
Pd-1 deficiency does not affect ILc-2 development
We next used a mixed BM chimera experiment to test two 
aspects of PD-1 function in KLRG1+ILC-2 biology, namely 
development and function. Mixed BM chimera experiments 
were performed in which T cell–depleted BM was adoptively 
transferred into WT B6 recipients after total body irradiation. 
8 wk after transplant, ILC-2 frequency and numbers were 
quantified. Murine recipients that received WT BM had a 
tendency toward lower numbers of KLRG1+ ILC-2s in the 
lungs compared with Pdcd1−/− recipients, but this difference 
did not reach significance (Fig. 2, A–E). A similar trend was 
noted in the small intestine and mesenteric LNs (Fig.  2, F 
and G). We next evaluated if ILC-2 cell development in the 
Pdcd1−/− mice was altered in the presence of WT BM (i.e., in 
the 1:1 mixed ratio cohort). Our data suggests that ILC-2 cell 
numbers in the WT and Pdcd1−/− compartments were not 
significantly altered in the mixed chimera cohorts (1:1 ratio). 
In addition, these data further identified an intrinsic function 
for PD-1 in regulating KLRG1+ ILC-2 numbers. In line with 
the increase in cell numbers, we also found that the IL-13 
cytokine production of KLRG1+ ILC-2s was increased in the 
lungs in the Pdcd1−/− cohorts but did not reach significance 
in 1:1 mixed chimera cohorts (Fig.  2, H and I). Therefore, 
lack of PD-1 did not alter KLRG1+ILC-2 cell development 
or function. To confirm the role of PD-1 in the development 
and intrinsic regulation of ILC-2s, experiments were repeated 
in Rag2−/−γc−/− hosts that lack host derived ILCs. These mu-
rine recipients were reconstituted with T depleted BM from 
WT or Pdcd1−/− mice. A significant increase in ILC-2 num-
bers were noted in the lungs of Pdcd1−/− BM recipients and 
a trend toward increase in ILC-2 cell numbers were noted in 
the small intestine (Fig. 2, J and K). No significant changes 
were noted in the ILC-2 cell numbers in the mixed chimera 
cohorts, both in the lungs and small intestine, which may 
indicate inhibitory signals from the WT compartment that 
can restrict Pdcd1−/− ILC-2 numbers. In summary the mixed 
chimera experiments demonstrate that PD-1 deficiency does 
not inhibit ILC-2 cell development.
Pd-1 intrinsically inhibits StAt5 signaling in KLrG1+ ILc-2s
Because our data suggested that PD-1 intrinsically regulated 
ILC-2 numbers, we next tested if PD-1 altered the prolif-
erative potential of KLRG1+ILC-2s. Lung-resident WT 
and Pdcd1−/− KLRG1+ ILC-2s were stimulated in vitro 
with various ILC-2 promoting cytokines, of which IL-33 in 
combination with IL-2 and IL-7 significantly enhanced the 
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Figure 1. characterization of ILc-2 subsets in Wt and Pdcd1−/− mice. Lungs, small intestine, and skin were harvested from WT and Pdcd1−/− mice, 
and then ILC-2 subsets were characterized by flow cytometry. Lin− was defined as CD3−, CD4−, CD8−, NK1.1−, GR1−, Ter119−, CD5−, CD11b−, CD11c−, 
F4/80−, CD45R/B220−, and CD19−. Gating strategy for ILCs included an initial gating of Lin−CD45+Thy1+. ILCs were then characterized as Lin−CD45+ Thy1+ 
CD127+CD25+ and ILC-2s as Lin−CD45+ Thy1+CD127+CD25+ST2+KLRG1+. Representative flow plots of ILC subset frequency in the lungs, small intestine, 
and skin in the WT and Pdcd1−/− mice (A). Summary of ILC frequency in the lungs, small intestine, and skin (B). Representative flow plots of ILC-2 subset 
frequency in the lungs in the WT and Pdcd1−/− mice (C). Summary of KLRG1+ ILC-2 frequency in the lungs, small intestine, and skin (D). Cytokine expression 
of ILC-2 subsets were measured by stimulating the cells with cell stimulation cocktail for 4 h, and expression of cytokines such as IL-5 and IL-13 were mea-
sured by flow cytometry. The expression of IL-5 and IL-13 by Lin−CD45+ Thy1+CD127+CD25+ST2+KLRG1+ in WT and Pdcd-1−/− mice; representative example 
in lungs (E) and summary in the various organs (F and G). KLRG1+ILC-2 cells from the lungs of WT mice were gated for PD1− and PD1+, and then the cytokine 
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proliferation of Pdcd1−/− ILC-2s compared with WT ILC-2s. 
No significant proliferative difference was noted with other 
ILC-2 cytokines, i.e., IL-25 and TSLP (Fig. S2, A and B). We 
next investigated if the in vitro effect was replicated in vivo 
on IL-33 priming of WT and Pdcd1−/− murine recipients. 
Toward this goal, WT and Pdcd1−/− mice were treated with 
rmIL-33 for 3 d as previously described (Maazi et al., 2015), 
and then numbers of KLRG1+ ILC-2s were determined. 
Compared with WT mice, Pdcd1−/− mice had significantly 
increased numbers of KLRG1+ ILC-2 cells (Fig.  3, A and 
B). No difference in effector cytokine frequency was noted 
between WT and Pdcd1−/− recipients (Fig. S2 C), but a sig-
nificant increase in the absolute numbers of IL-13+KLRG1+ 
cells was observed (Fig. 3 C). We next investigated if in vivo 
IL-33–stimulated KLRG1+ ILC-2s had enhanced prolifera-
tive potential. Our data demonstrated that KLRG1+ILC-2s 
from Pdcd1−/− mice had significantly enhanced proliferative 
capacity (Fig. 3, D and E).
On identifying the in vitro and in vivo effect of IL-33, 
the influence of IL-25 was investigated. IL-25 treatment did 
not alter the frequency and numbers of KLRG1+ ILC-2s in 
the Pdcd1−/− mice (Fig. S2, D and E).
The signaling pathways that resulted in an increase in 
KLRG1+ ILC-2 cells in Pdcd1−/− mice were next explored. 
Because ILC-2s depend on STAT5 signaling for proliferation 
and PD-1 inhibits STAT5 signaling in T cells (Franceschini 
et al., 2009), we explored if a similar mechanism operated 
in ILC-2s. To measure STAT5 signaling in the KLRG1+ 
ILC-2 subsets, WT and Pdcd1−/− mice were either treated 
with PBS or rmIL-33 for 1 d, as previously described (Maazi 
et al., 2015). KLRG1+ILC-2s were then ex vivo stimulated 
with IL-2 for 15 min, and then subjected to phospho-STAT5 
flow cytometry. STAT5 signaling was significantly enhanced 
in the Pdcd1−/− KLRG1+ ILC-2 subsets that were treated 
with either PBS or rmIL-33 (Fig. 3 F). We next investigated 
if providing PDL-1 ligand had an effect in inhibiting STAT5 
activation in WT KLRG1+ ILC-2 subsets. For these exper-
iments, WT and Pdcd1−/− mice were treated with IL-33 for 
3 d, and then KLRG1+ ILC-2 cells were stimulated in the 
presence of plate-coated PDL-1 fc-chimera plus IL-2 or IL-2 
alone for 15 min, and then phospho-STAT5 flow cytometry 
was performed. In the WT mice treated with rmIL-33, suf-
ficient STAT5 signaling was noted, which was significantly 
decreased in the presence of PDL-1 (Fig. 3, G and H). No 
difference in p-STAT5 signaling was detected in the Pdcd1−/− 
cohorts treated with PDL-1. In addition, these data suggest 
that ILC-2s from Pdcd1−/− mice exhibit robust STAT5 acti-
vation (one dose of in vivo IL-33), and this effect is recapit-
ulated in the WT ILC-2s after three doses of in vivo IL-33. 
The initial boost in STAT5 activation, along with lack of re-
sponse to PDL-1–mediated inhibitory effects, may contribute 
toward significant proliferation in the Pdcd1−/− cohorts.
To further explore this mechanism, we sequentially 
inhibited PD-1 or its downstream signaling components, 
namely SHP1/2 in ex vivo culture of KLRG1+ILC-2s. IL-33 
was administered to WT and Pdcd1−/− mice for 3 d, and then 
KLRG1+ILC-2s were stimulated for 24 h in the presence of 
IL-2, IL-7, and IL-33. Certain cohorts were treated with an 
isotype control antibody (denoted as control in figure), anti–
PD-1 antibody, selective SHP1/2 inhibitor (NSC87877), 
PDL-1 fc, and PDL-1 fc+SHP1/2 inhibitor. After 24-h stim-
ulation, cells from the various cohorts were restimulated for 
15 min with IL-2, and then subjected to phospho-STAT5 
flow cytometry. We found that blocking PD-1 or its signal-
ing pathway significantly increased p-STAT5 activation in 
KLRG1+ ILC-2s. This increase in p-STAT5 was inhibited 
when the PD-1 pathway was activated instead of blocked (by 
providing the ligand PDL-1fc). Inhibition of p-STAT5 in the 
cohorts that were treated with PDL-1 fc was significantly re-
versed upon blocking SHP1/2 (Fig. 3 I). Collectively, these 
data suggest that altering PD-1 signaling in KLRG1+ILC-2s 
can modulate STAT5 activation. The impact of these con-
ditions (PD-1 signaling blockade) on nuclear STAT5a/b 
content in KLRG1+ILC-2s was investigated. A similar ex-
perimental approach was used, but the cells were expanded 
for 72 h instead of 24 h. After stimulation, cells from the dif-
ferent cohorts were isolated and nuclear extracts were pre-
pared and subjected to a nuclear transcription factor assay. 
We found that blocking PD-1 significantly increased nuclear 
STAT5 in KLRG1+ILC-2s. An increase was also noted in 
the presence of SHP1/2 blocker, but did not reach statistical 
significance. Providing PDL-1 fc in these long-term cultures 
did not alter STAT5a nuclear content, but blocking SHP1/2 
(in the PDL-1 fc group) did increase the content of nuclear 
STAT5a in KLRG1+ ILC-2s (Fig. 3 J). The nuclear content of 
STAT5b showed a similar profile to that of STAT5a (Fig. S2 
f). Next, we investigated the reason for the lack of PDL-1 fc 
effect in long-term cultures. We found that IL-33 stimulation 
for 72 h up-regulated PDL-1 expression on KLRG1+ILC-2s 
(Fig. S2  g), suggesting that providing PDL-1 fc as a ligand 
may be redundant under these stimulating conditions. We 
finally evaluated the proliferation of KLRG1+ ILC-2s under 
these various culture conditions. Blocking PD-1 or SHP1/2 
significantly enhanced the proliferative potential of KLRG1+ 
ILC-2s, which was significantly inhibited by PDL-1 fc stimu-
lation. Similar to the p-STAT5 assays, blocking SHP1/2 in the 
presence of PDL-1 fc reversed the proliferative effect (Fig. S2, 
Ha and I). Therefore, these data suggest that modulating PD-1 
signaling in KLRG1+ ILC-2s can alter STAT5 activation sta-
tus and can also affect proliferation in long-term cultures.
profile was monitored by intracellular flow cytometry (H and I). Experiments were repeated three times reproducibly, and data shown are from n = 3–5 mice 
for all panels. Data shown is mean ± SEM. A Student’s t test was performed to determine statistical significance between the various cohorts. P ≤ 0.05 was 
considered significant. Significant p-values are denoted in the figures.
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Next, we explored if PD-1 signaling independently 
(bypassing STAT5) affected proliferation of KLRG1+ ILC-2s. 
We found that co-injection of both IL-33 and Tofacitinib 
(JAK/STAT inhibitor) in Pdcd1−/− mice significantly re-
duced KLRG1+ ILC-2 cell numbers and IL-13 cytokine 
production in the lungs (Fig.  3, K–M; and Fig. S2, J and 
K). These data demonstrate that the PD-1 pathway does 
not operate independently of STAT5 in inducing prolif-
eration of KLRG1+ ILC-2s.
Pdcd1−/− KLrG1+ILc-2s gene expression pattern indicates 
enhanced effector function
To further explore the molecular mechanism of PD-1 reg-
ulation on ILC-2 cells, we performed a microarray assay to 
compare gene expression patterns of KLRG1+ ILC-2s be-
tween WT and Pdcd1−/−. Dozens of differentially expressed 
genes were identified, with 45 genes up-regulated and 7 
down-regulated in Pdcd1−/− (false discovery rate [FDR] 
≤ 0.15). Consistently, the expression levels of STAT5 tar-
get genes (e.g., slamf1 and csf1) were increased in PD-1– 
deficient KLRG1+ ILC-2s, whereas cell proliferation or 
activation-associated genes (e.g., klra9 and lztfl1) were also 
altered (Fig.  4  A). Gene ontology enrichment analysis of 
up-regulated genes revealed that the lack of PD-1 affected 
signaling pathway on ILC-2s, including innate immune re-
sponses, macrophage chemotaxis, cell-cell interaction and 
metabolism (Fig. 4 B). We also performed gene set enrich-
ment analysis against published gene set (Duraiswamy et al., 
Figure 2. Pd-1 deficiency does not alter ILc-2 cell development. Host CD45.1+C57BL6 mice were subjected to total body irradiation (1,050 cGy), and 
then reconstituted with either CD45.1+ WT BM (10 million) or CD45.2+Pdcd1−/− BM (10 million). Some cohorts received both WT and Pdcd1−/− BM at a 1:1 
ratio (5 million WT :5million Pdcd1−/−). At 8 wk after BM transplant, ILC-2 were analyzed by flow cytometry via gating on Lin− CD45+ Thy1+ CD127+ CD25+ 
ST2+ KLRG1+ (Representative data from lungs; A–D) and cell numbers were characterized in the lungs, small intestine, and mesenteric LNs. Summary of the 
absolute numbers of KLRG1+ILC-2 cells in the lungs (E), small intestine (F), and mesenteric LNs (G). Single-cell suspensions were stimulated with cytokine 
stimulation cocktail, and cytokine profile was measured by flow cytometry. Summary of absolute numbers of IL-5 and IL-13 from lung KLRG1+ILC-2s 
(H and I). Host C57BL6 Rag−/−γc−/− mice were reconstituted with either CD45.1+ WT BM (10 million), or CD45.2+Pdcd1−/− BM (10 million). Some cohorts 
received both WT and Pdcd1−/− BM at a 1:1 ratio. At 8 wk after BM transplant, the lung and small intestine were harvested from the mice and KLRG1+ILC-2 
cell numbers were characterized. Summary of the absolute numbers of KLRG1+ILC-2 cells in the lungs (J) and small intestine (K) in the various cohorts was 
analyzed by flow cytometry. Animals per cohort was n = 5. Data shown are mean ± SEM. Experiments were repeated twice. A one-way ANO VA analysis 
followed by a multiple comparison test [Turkey] was performed to determine statistical significance between the various cohorts. P ≤ 0.05 was considered 
significant. Significant p-values are denoted in the figures.
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Figure 3. Lack of Pd-1 signaling results in a significant increase in KLrG1+ ILc-2 numbers. WT and Pdcd1−/− mice were either treated with PBS or 
IL-33 (200 ng/mice) for 3 d. ILC-2 frequency and numbers were evaluated by flow cytometry at day 3. Gating strategy include: Lin−CD45+ Thy1+CD127+ 
CD25+ST2+KLRG1+. Representative flow plots of KLRG1+ILC-2 subsets in WT and Pdcd1−/− (A) and summary of absolute numbers of KLRG1+ ILC-2 in WT 
and Pdcd1−/− lungs were evaluated (B). Cytokine expression of ILC-2 subsets were measured by stimulating the cells with cell stimulation cocktail for 4 h, 
and expression of cytokines such as IL-5 and IL-13 were measured by flow cytometry. The absolute number of IL-13+ cells within Lin−CD45+ Thy1+CD127+ 
CD25+ST2+KLRG1+ in WT and Pdcd-1−/− mice (C). Ki67 staining in the different cohorts were analyzed by flow cytometry (D and E). WT or Pdcd-
1−/− were treated with PBS or IL-33 (200ng/mice) for 1 d. Lung ILC-2 cells were isolated, and then restimulated with IL-2 for 15 min, followed by 
phospho-STAT5 flow cytometry. Summary of the frequency of p-STAT5 signaling in the various cohorts (F). Experiments were repeated where WT or 
Pdcd-1−/− mice were treated with PBS or IL-33 (200 ng/mice) for 3 d. Lung ILC-2 cells were restimulated with IL-2 alone or IL-2 along with coated 
PDL-1fc chimera (5 µg/ml) for 15 min, followed by phospho-STAT-5 flow cytometry. Representative flow plots showing p-STAT5 signaling in WT (G; 
top) or Pdcd-1−/− (G; bottom). Summary of the frequency of p-STAT5 signaling in the various cohorts (H). Experiments were repeated where WT mice 
were treated with IL-33 (200 ng/mice) for 3 d, and lung ILC-2s were stimulated for 24 h with IL-2, IL-7, and IL-33. In addition, cohorts were treated 
with Isotype control antibody, αPD-1 antibody, NSC87877, PDL-1fc, or PDL-1 Fc plus NSC87877. After 24-h stimulation, cells were restimulated 
with IL-2 (100 ng/ml) and subjected to p-STAT5 flow cytometry. Mean fluorescence intensity of p-STAT5 in KLRG1+ILC-2s from various cohorts (I). 
Experiments were repeated, and ILC-2s were stimulated in vitro for 3 d, and then nuclear lysates were tested for STAT5a (J). Mechanistic experiments 
were set up with WT and Pdcd1−/− mice, where cohorts were treated with rmIL-33 + Vehicle (DMSO) or with rmIL-33 + Tofacitinib (15mg/kg/d/
mouse). Absolute numbers of KLRG1+ILC-2s were evaluated at day 3 after treatment (K), and functional cytokine expression was monitored in the 
various cohorts (L and M). Animals per cohort was n = 5. Data shown are mean ± SEM and cumulative of at least two repeats. A one-way ANO VA 
analysis followed by a multiple comparison test (Tukey) was performed to determine statistical significance between the various cohorts. P ≤ 0.05 
was considered significant. Significant p-values are denoted in the figures.
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2011) and the result showed that PD-1 deficiency had simi-
lar impact on gene expression patterns between ILC-2s and 
CD8+ T cells (FDR q-value = 0.036; Fig. 4 C), suggesting 
that a similar intrinsic regulatory mechanism of PD-1 signal 
may apply to both innate and adaptive lymphocytes.
KLrG1+ILc-2 cells from Pdcd1−/− mice 
possess anti-helminth immunity
We next evaluated if PD-1 deficiency modulated ILC-2 func-
tion during parasitic helminth infections. To investigate this, 
WT and Pdcd1−/− mice were infected with N. brasiliensis, 
and then KLRG1+ ILC-2 subset numbers were evaluated. In 
the lungs, the frequency and numbers of ILC-2 (GATA3+) 
or KLRG1+ ILC-2 subsets were similar in both WT and 
Pdcd1−/− cohorts on day 5 after worm infection (Fig. S3). 
In the Pdcd1−/− mice, near the site of infection (mesenteric 
LNs; MLNs), a significant increase in GATA3+ILC-2 fre-
quency (Fig. 5 A) and absolute numbers (Fig. 5 B) was noted. 
In addition a significant increase in KLRG1+ ILC-2 subset 
frequency (Fig. 5 C), absolute numbers (Fig. 5 D), and cy-
tokine production (Fig.  5, E–G) was also noted. Next, the 
function of the Pdcd1−/− KLRG1+ ILC-2 cells independent 
of adaptive immunity in clearing worm burden was evalu-
ated. For these experiments, Rag2−/−γc-/− mice were in-
fected with N. brasiliensis, followed by adoptive transfer of 
either WT or Pdcd1−/− KLRG1+ ILC-2 cells. A significant 
difference in the worm burden (Fig.  5 H) and worm eggs 
(Fig. 5 I) was noted in recipients that were reconstituted with 
Pdcd1−/− KLRG1+ ILC-2 subsets.
Blocking Pd-1 in rag1−/− mice enhances ILc-2 function 
during parasitic helminth infections
Experiments were performed to identify if exogenous 
blocking of PD-1 using an antibody would have similar ef-
Figure 4. comparison of gene expression profiles of KLrG1+ ILc-2s between Wt and Pdcd1−/−. Lin−CD90+KLRG1+ ILC-2s were sorted from 
the lungs of WT or Pdcd1−/− mice that had been treated with IL-33 for 3 d. Total RNA was isolated, and then subjected to microarray analysis. Heat map for 
the expression patterns of differentially expressed genes (A). Representative GO terms enriched for genes up-regulated in Pdcd1−/−. Only GO terms from the 
biological process category is shown. The log10-scaled p-value is indicated in the x axis (B). Gene set enrichment analysis of the effect of Pdcd1 knockout 
for gene expression. The genes are ranked by fold change as evaluated by microarray data, and compared with the gene set available from GEO under 
accession no. GSE26495 (NAI VE_VS_PD1LOW_CD8_TCE LL_DN). The blue curve shows the running enrichment score (ES) for the gene set as the analysis 
walks down the ranked gene list. The leading edge for the gene set is shown as short bars at the bottom. The normalized enrichment score (NES) is calcu-
lated as –1.51, and the false discovery rate FDR is calculated as 0.036 (C). A one-way ANO VA analysis was performed to determine statistical significance. 
Microarray analysis was performed in triplicates, and each experiment consisted of n = 5 mice per cohort.
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fects on KLRG1+ ILC-2 subsets in vivo. Rag1−/−mice were 
injected with either isotype or αPD-1 antibody at day 0, 
and then treated with rm-IL-33 from day 1 to 3. In cohorts 
that were treated with both αPD-1 and rmIL-33 cytokine, 
a significant increase in KLRG1+ ILC-2 cell frequency 
numbers was noted (Fig. 6, A and B). To identify if block-
ing PD-1 can enhance therapeutic potential via ILC-2 cells, 
we repeated PD-1 blocking experiments in Rag1−/− mice 
infected with N. brasiliensis. Blocking PD-1 during ongo-
ing helminth infection significantly enhanced ILC-2 num-
bers (Fig. 6 C) and cytokine production in MLNs (Fig. 6, 
D and E) and diminished both worm eggs in the feces 
(Fig. 6 F) and worm burden (Fig. 6 G). These results iden-
tify a potential wider application for anti–PD-1 therapeu-
tics in helminth infections.
Pd-1 regulates KLrG1+ ILc-2s in humans
We next explored if PD-1 is expressed on ILC subsets in 
human PBMCs. PD-1 was almost exclusively expressed on 
ILC-2s as compared with ILC-1 and ILC-3 subsets (Fig. S4, 
Figure 5. KLrG1+ ILc-2 cells from Pdcd1−/−are efficient at clearing n. brasiliensis from rag−/−γc−/− mice. WT or Pdcd1−/− mice were infected 
with N. brasiliensis, and then KLRG1+ ILC-2 numbers in the mesenteric LNs were evaluated by flow cytometry. Representative flow plots showing GATA3+ 
ILC-2 frequency in the WT and Pdcd1−/− (A), summary of absolute numbers of GATA3+ILC-2+ cells (B), representative flow plots showing KLRG1+ILC-2 subset 
frequency in WT and Pdcd1−/− mice (C), and absolute numbers of KLRG1+ ILC-2 numbers in WT and Pdcd1−/− mice (D). Functional cytokine expression was 
monitored using intracellular flow cytometry, and both frequency and absolute numbers were measured (E–G). Rag2−/−γc−/− mice were infected with N. 
brasiliensis, and then reconstituted with either WT or Pdcd1−/− KLRG1+ ILC-2 cells. Worm burden (H) and eggs in the feces (I) of host mice is shown. Black 
circles represent WT and gray squares represent Pdcd1−/−. Animals per cohort was n = 4–5, and data shown are mean ± SEM. Experiments were performed 
twice; data shown is from one repeat. A Student’s t test was performed to determine statistical significance between the various cohorts in all the panels. 
P ≤ 0.05 was considered significant. Significant p-values are denoted in the figures.
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A and B). On further characterization based on IL-7Rα, 
KLRG1, and GATA3, we found that human KLRG1 sub-
sets also expressed PD-1 at a similar frequency to murine 
ILC-2s (Fig. 7, A and B). Similar to murine data, PD-1+ sub-
sets secreted significantly lower amounts of IL-5 and IL-13 
compared with PD-1− subsets (Fig.  7, C and D). We next 
evaluated if PD-1 also intrinsically inhibited STAT5 signal-
ing in human ILC-2s. STAT5 signaling was enhanced when 
PD-1 was blocked on ILC-2s, and this effect was reversed 
by the JAK/STAT inhibitor Tofacitinib (Fig. 7, E and F). 
We next investigated if nuclear STAT5a/b content in 
KLRG1+ILC-2s is altered when PD-1 pathway is manipu-
lated. Similar to murine data, blocking PD-1 resulted in an in-
crease in STAT5a/b nuclear content in human ILC-2s (Fig. S4, 
C and D). After this, we evaluated the downstream effects 
of STAT5 activation on ILC-2 proliferation. PD-1+GATA3+ 
cells were inherently less proliferative as compared with the 
PD-1−GATA3+ ILC-2s (Fig. 7 G; and Fig. S4, E and F). On 
inhibiting PD-1 signaling, an increase in proliferation was 
noted, which was reversed on inhibiting Jak/STAT signaling 
through Tofacitinib (Fig. 7 G; and Fig. S4, E and F). In sum-
mary, PD-1 intrinsically regulates human KLRG1+ ILC-2s by 
inhibiting STAT5 phosphorylation.
We next investigated if blocking PD-1 by antibody 
treatment increased human ILC-2 numbers and function in 
vivo. Initial experiments suggested that similar to our mu-
rine data, IL-33 was the most efficient stimuli that induced 
robust proliferation of PD-1+ ILC-2 cells (Fig. S4 G). NSG 
recipients were reconstituted with PBMCs and then treated 
with anti-PD-1 antibody along with rhIL-33 for 3 d. We 
Figure 6. Administration of αPd-1 can significantly diminish worm burden in rag1−/−recipients. Rag1−/− mice were treated with isotype or αPD-1 
antibody (250 µg/mice), followed by rmIL-33 (200 ng/mice), for 3 d. Gating strategy included Lin−CD45+ Thy1+CD127+CD25+ST2+KLRG1+. Representative 
flow plots of ILC-2 in Isotype and αPD-1 cohorts (A) and summary of absolute numbers of KLRG1+ ILC-2 in Isotype and αPD-1 cohorts’ lungs (B) were 
evaluated. Rag1−/− mice were infected with 300 Larvae 3 of N. brasiliensis on day 0. Anti–mouse PD-1 antibodies or IgG isotype control were i.p. injected 
into mice on day 0, 3, 6, and 9, at a dose of 250 µg antibody per mouse each time. Leukocytes were isolated from MLNs on day 14, and the numbers of 
total ILC-2 cells were analyzed by flow cytometry (C). Cytokine expression was analyzed using intracellular flow cytometry (D and E). Feces were collected 
on day 7, 8, and 9 from individual mouse, and the worm eggs were counted (F). Adult worms in small intestine were counted on day 14 (G). Animals per 
cohort was n = 4–5. Data shown are mean ± SEM. Experiments were repeated twice. Data on n = 5 mice is shown (A–C). A Student’s t test was performed to 
determine statistical significance for the data shown in all the panels. P ≤ 0.05 was considered significant. Significant p-values are denoted in the figures.
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found that blocking PD-1 significantly enhanced cytokine 
production in GATA3+KLRG1+ cell subsets (Fig. 7 h). The 
enhanced cytokine secretion capacity of ILC-2s was inhibited 
in cohorts that received Tofacitinib in addition to rhIL-33 
and αPD-1 antibody treatment. Therefore, in humans PD-1 
negatively regulates KLRG1+ ILC-2 cells by modulating the 
STAT5 activation pathway.
dIScuSSIon
Approximately one-third of the world’s population is infected 
with one or more types of parasitic helminth worms however 
treatment options for these ubiquitous infections are limited 
(Hotez et al., 2008). Type 2 immune responses, which are 
initiated by ILC-2s, are pivotal in clearing helminth worms 
in adults, but the regulatory pathways that can modulate the 
Figure 7. Pd-1 regulation of KLrG1+ILc-2 is conserved in human PBMcs. Human PBMCs were obtained from normal healthy volunteers and 
characterized for the expression of PD-1 in the various ILC subsets. Gating strategy included Lin−CD45+CD127+GATA3+KLRG1+ (A). PD-1 expression was 
analyzed in n = 5 donors (A and B). ILC-2 cells were gated as either GATA3+PD-1− or GATA3+PD-1+, and then characterized for cytokine expression (C and 
D). PBMCs were stimulated with rhIL-2 (1,000 IU) + Vehicle (DMSO) + Isotype control for 15 min, and then p-STAT5 expression was measured by flow 
cytometry. Certain cohorts were treated with rhIL-2 + Vehicle + αPD-1 or rhIL-2 + Tofacitinib (0.3 µM) + αPD-1. The representative flowplot and mean 
fluorescence intensity of pSTAT5 in various cohorts were measured by flow cytometry (E and F; n = 4 donors). PBMCs were labeled with Cell Trace Violet. 
and then ILC-2s were stimulated with rhIL-2 + rhIL-7 (40 ng/ml) + Vehicle (DMSO) + Isotype control or with rhIL-2 + rhIL-7 + Vehicle + αPD-1 or with 
rhIL-2 + rhIL-7 + Tofacitinib + αPD-1. Dilution of Cell Trace Violet as a measure of proliferation was performed at day 5 after stimulation (G; n = 4 donors). 
Experiments were performed in multiple donors as stated, and data are represented as mean + SEM. Human PBMCs (4 million) were adoptively transferred 
into NSG murine recipients and treated with rhIL-2, rhIL-7, and rhIL-33 for 3 d, along with Vehicle (DMSO) and Isotype control antibody. This cohort is 
termed as control; certain cohorts received either αPD-1 or αPD-1 and Tofacitinib, in addition to rhIL-2, rhIL-7, and rhIL-33. At day 3 after adoptive transfer, 
lungs were harvested and stimulated with PMA/ionomycin, and then human ILC-2 subsets were characterized. Human CD45+ cells were gated followed by 
CD45+Lin− CD127+GATA3+KLRG1+ gating. Cytokine expression of KLRG1+ ILC-2s were evaluated in the various cohorts (H). For in vivo experiments, each 
cohort had n = 4 mice; data are represented as mean ± SEM. A Student’s t test was performed to determine statistical significance in C and D, and a one-way 
ANO VA analysis followed by a multiple comparison test [Tukey] was performed to determine statistical significance between the various cohorts in F–H. 
P ≤ 0.05 was considered significant. Significant p-values are denoted in the figures.
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function of ILC-2s are still largely unexplored. Emerging lit-
erature on ILC-2 populations in mice and humans (Maazi et 
al., 2015; Molofsky et al., 2015; Paclik et al., 2015; Seillet et 
al., 2016; Yu et al., 2016), combined with the data presented 
here, has identified a pivotal role for co-receptor–mediated 
regulation of ILC-2s. Whereas immune-activating signals that 
maintain ILC-2s have been extensively studied, there is pau-
city in understanding the regulatory pathways that modulate 
ILC-2 cell number and function in vivo.
This report is the first to demonstrate that IL-33– 
responsive KLRG1+ ILC-2s are regulated by PD-1 in both 
mice and humans. When ILC-2s are activated by IL-33 
(through the IL-33 receptor ST2), they respond by secreting 
type 2 cytokines and up-regulate KLRG1. Our data indicates 
that PD-1 selectively inhibits the proliferation of KLRG1+ 
ILC-2s via modulating STAT5 function. Here, we propose 
a new regulatory axis, whereby activated mature KLRG1+ 
ILC-2s up-regulate PD-1 on exposure to IL-33. PD-1 then 
inhibits uncontrolled expansion of ILC-2 effector popula-
tion by blocking proliferation. PD-1, therefore, is a critical 
negative checkpoint and contributes toward maintaining 
KLRG1+ ILC-2 cell numbers.
Recent studies indicated that PD-1 is a novel maker for 
ILC precursors (Yu et al., 2016), but whether PD-1 could 
regulate the development and function of ILCs, particularly 
ILC-2s, was unclear. We observed that, first, the frequency of 
mature KLRG1+ ILC-2s was increased in the Pdcd1−/− mice; 
second, reconstituted Pdcd1−/− ILC-2 cells were capable of 
secreting functional cytokines; and third, ILC-2 cell devel-
opment was not compromised when BM from Pdcd1−/− 
mice was adoptively transferred into immune-deficient 
Rag2−/−γc−/− mice. Notably, Seillet et al. (2016) observed 
that Pdcd1−/− mice possess a similar frequency of ILC-2 pre-
cursors to WT mice. In addition, PD-1 has been suggested 
to be a marker on ILC-2 precursors (Yu et al., 2016). Our 
study is the first to identify a mechanistic role for PD-1 
in mature ILC-2 and propose that although PD-1 is ex-
pressed on ILC-2 precursors, lack of PD-1 does not alter 
ILC-2 development or their cytokine production capacity in 
mixed chimera experiments.
In keeping with most ILC subsets, ILC-2s are respon-
sive to γc cytokines (Bartemes et al., 2012) and explicitly de-
pend on γc cytokines and STAT5 signaling for proliferation 
and survival. A specific increase in proliferation was noted in 
the Pdcd1−/− ILC-2s, which then led us to investigate the 
interplay between PD-1 and STAT5 signaling in these cells. 
Notably, STAT5 signaling can be modulated by co-receptors 
such as ICOS in ILC-2s (Maazi et al., 2015), and PD-1 signal-
ing can inhibit T cell function and proliferation by dampen-
ing STAT5 (Francisco et al., 2009). In agreement with these 
previous studies, a significant increase in STAT5 phosphory-
lation and proliferation was noted in KLRG1+ ILC-2 num-
bers in Pdcd1−/− recipients, which was conserved in human 
ILC-2s. In all these studies (Francisco et al., 2009; Maazi et 
al., 2015), the PD-1 activating ligand that was primarily re-
sponsible for inhibiting STAT5 signaling is PDL-1, and hence 
we used a similar experimental methodology in the current 
study. We found that PDL-1 binding to PD-1 specifically 
down-regulated STAT5 activation in KLRG1+ ILC-2s.
Although the importance of PD-1 signaling in inhib-
iting STAT5 activation has been previously suggested in T 
cells (Francisco et al., 2009), two caveats remain. First, no di-
rect mechanistic evidence has linked these pathways; second, 
it is not clear whether similar mechanisms exist in ILC-2s. 
Our in vitro and in vivo mechanistic data in murine and 
human ILC-2s has demonstrated that inhibiting or induc-
ing PD1 signaling pathway can alter STAT5 activation on 
KLRG1+ILC-2s. Importantly, PD-1 does not operate inde-
pendently of STAT5 in promoting ILC-2 cell proliferation.
In addition to cellular mechanisms, we sought to verify 
if Pdcd1−/− KLRG1+ ILC-2s exhibited a gene profile that 
correlated with enhanced effector function. The microarray 
data suggested that ILC-2s deficient in PD-1 had increased 
expression of STAT5 target genes such as slamf1 (Wang et al., 
2015), and STAT5 activating genes such as csf1 (Novak et al., 
1996). Of note, the gene profile of Pdcd1−/− ILC-2s followed 
a pattern that is found in effector memory CD8+ T cells. 
In particular, we found that klra9, which identifies exhaustion 
in CD8+ T cells (Wherry et al., 2007), was down-regulated in 
Pdcd1−/− ILC-2s. Gene set enrichment analysis further cor-
related with the cellular mechanistic assays in highlighting the 
enhanced effector function of Pdcd1−/− KLRG1+ILC-2s.
The function of Pdcd1−/− KLRG1+ILC-2 cells was 
found to be superior to their WT counterparts in eliciting 
host-mediated pathogen responses in in vivo worm expulsion 
experiments. Given that KLRG1+ ILC-2 subsets are important 
in the expulsion of worms (Huang et al., 2015), the potency 
of these Pdcd1−/− KLRG1+ILC-2 cells in Rag2−/−γc−/− iden-
tifies a new therapeutic role for PD-1 in inducing robust 
type 2 responses. Furthermore, the differential numbers of 
KLRG1+ILC-2 cells in the MLNs of Pdcd1−/− mice during 
infection suggests the importance of PD-1 as a checkpoint 
modulator that can regulate ILC-2 cell numbers in the MLN 
during host–pathogen–mediated immune responses. Of note 
is the lack of difference in ILC-2 cell numbers in the lungs 
of infected Pdcd1−/− mice. N. brasiliensis life cycle includes 
migration through the lungs; however, a clear difference in 
WT and Pdcd1−/− mice with respect to ILC-2 cell num-
bers was not observed. Hence, alternate regulatory mecha-
nisms independent of PD-1 may inhibit ILC-2s in different 
organs during parasitic infections. This differential increase in 
ILC-2 numbers could be important in translating these f ind-
ings to helminth immunity.
To confirm the potential therapeutic benefits in host–
pathogen–mediated immune responses, PD-1 antibody ex-
periments were performed in Rag1−/− recipients that were 
infected with N. brasiliensis. To date, the data presented here 
is the first to show that αPD-1 therapy results in an increase in 
KLRG1+ ILC-2 numbers, which is reflected in a significant 
decrease in worm burden. These results suggest that block-
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ing PD-1 can skew immune responses to type 2 phenotype, 
thereby inducing strong antiparasitic responses. In addition, 
this observation can be extrapolated to the cancer immuno-
therapy trials (Topalian et al., 2012; Yaqub, 2015), whereby the 
primary reason for reduced autoimmune colitis in patients 
who receive PD-1 therapy can be attributed to increased type 
2 responses (Ruyssers et al., 2009; Bashi et al., 2015).
Lastly, the murine N. brasiliensis experiments in 
Rag−/−γc−/− mice demonstrated that PD-1 intrinsically reg-
ulates ILC-2 cell function with minimal contribution from 
bystander immune cells. In the adoptive transfer experiments, 
murine recipients reconstituted with Pdcd1−/− ILC-2s had 
significantly lower worm burden than the WT cohorts. These 
data demonstrate that an intrinsic defect in PD-1 signaling in 
ILC-2s contribute to robust antiparasitic helminth responses. 
Indeed, if PD-1 elicits its function through bystander immune 
cells, no difference between cohorts that received WT and 
Pdcd1−/− ILC-2s will be noted.
In summary, we have demonstrated that ILC-2 cells are 
regulated by PD-1, lack of which enhances KLRG1+ ILC-2 
cell numbers and effector function. The cellular signaling 
mechanism by which KLRG1+ ILC-2 cell numbers are in-
creased in Pdcd1−/− mice is through enhanced STAT5 acti-
vation, which results in elevated γc cytokine–mediated cell 
proliferation and cytokine secretion. Collectively, these data 
represent an ideal translational route to manipulating ILC-2 
cell numbers in vivo. Therefore, PD-1 blockade may be ben-
eficial in situations that require significant ILC-2 cell num-
bers (helminth immunity) and this effect can be controlled 
by Tofacitinib to prevent deleterious uncontrolled type 2 
inflammatory processes.
MAterIALS And MethodS
Mice
Wild-type C57BL/6 (B6) and B6.Pdcd1−/− littermates were 
bred and maintained in a specific pathogen–free facility at 
the National Cancer Institute (NCI; Bethesda, MD). Mice 
were housed and maintained according to National Insti-
tutes of Health guidelines and all experiments were per-
formed in accordance with the NCI Animal Care and Use 
Approval and institutional guidelines. All mice used in the 
experiments were age and sex-matched. CD45.1+ C57BL6, 
NOD-SCID-γc−/− (NSG) and B6. Rag2−/−γc−/− mice were 
obtained from Jackson Laboratories and maintained at the 
NCI or at Newcastle University, UK under a home office 
approved project license. All the experimental procedures 
performed at Newcastle University incorporated the NC3R 
guidelines for animal research, and the data were presented 
according to the ARR IVE guidelines.
Isolation of ILc-2 cells and ex vivo stimulation
Spleens and MLNs were mechanically crushed into single- 
cell suspensions. Lungs and small intestine were digested in 
Liberase TL (Roche) and DNase (Roche; Asseman et al., 
2003), and ILCs were isolated as previously described. For 
skin ILCs, a small piece of mouse dorsal skin was removed, 
minced, and incubated with serum-free media containing 
Liberase TL and DNase at 37°C. Single-cell suspensions were 
prepared by mashing the tissue slurry through a 100-µm 
nylon mesh. Cells were sequentially filtered through 70- and 
40-µm nylon filters. To assess production of cytokines, both 
murine and human ILC-2s were stimulated for 4 h in com-
plete RPMI + 10% FBS with cell stimulation cocktail (PMA, 
ionomycin, Brefeldin A, and monensin; eBioscience) as per 
manufacturer’s instruction, followed by intracellular staining. 
Unstimulated controls were used to determine gating strategy 
for flow cytometric plots in figures. All human-derived mate-
rials were collected under an approved ethics plan (Durham 
and Tees Valley Research Ethics Committee [12/NE/0121], 
granted 16th April 2012).
BM mixed chimera experiments
BM cells from B6 or B6.Pdcd1−/− mice were harvested and 
T cell depleted. Congenic recipients B6.CD45.1+ mice were 
conditioned with total body irradiation (1,050 cGy) and 
rescued with 10million T-depleted BM (TDBM) cells from 
B6.CD45.1+ WT or B6 CD45.2+ Pdcd-1−/−mice. 8 wk later, 
lungs and small intestine were digested and immune cells 
were isolated followed by ILC-2 subsets characterization. 
Experiments were repeated in host B6.Rag2−/−γc−/− mice, 
where mice were reconstituted with either congenic WT BM 
(CD45.1) or Pdcd1−/−BM (CD45.2).
Flow cytometry
The following fluorochrome-conjugated antibodies were 
used for flow cytometry. Anti-CD3ε (145-2c11), anti-CD8 
(53-6.7), anti-CD19 (6D5), anti–Gr-1 (RB6-8C5), anti-
KLRG1 (2F1/KLRG1), anti-CD25 (PL61), anti-CD45.2 
(104), anti–PD-1 (RMP1-30), anti-CD4 (GK1.5), anti–
IL-5 (TRFK5), anti-CD45.1 (A20), anti-CD127 (A7R34), 
anti-CD25 (PC61), anti-CD5 (53-7.3), anti-CD11c (N418), 
anti-CD11b (M170), anti-Ter119, anti-CD45R/B220, and 
anti-F4/80 (BM8) were obtained from BioLegend. Anti–IL-4 
(11B11) and anti-Thy1 (53–2.1) were obtained from BD. 
Anti-KLRG1 (2F1), anti-Ki67 (SoLA15), anti-Gata3 (TWAJ), 
and anti–IL-13 (eBio13A) were purchased from eBioscience. 
Anti-ST2 (DJ8) was obtained from MD Bioproducts. Single-
cell suspensions were generated from indicated organs, and 
then incubated with anti-Fc receptor antibody (2.4G2) and 
stained with Lin PE-Cy5.5 (CD3+, CD4+, CD8+, NK1.1+, 
Gr1+, CD5+, Ter119+, CD11b+, CD11c+, F4/80+, CD45R/
B220+, and CD19+), CD45 APC-Cy7, KLRG1 BV421 or 
APC-Cy7, ST2 FITC, GATA3 efluor660, and PD-1 BV605, 
CD127 BV510 or BV711, CD25 Pe-cy7, PDL-1 BV711, 
Thy1 PE. For intracellular (IC) cytokine measurement, 
cells were fixed, permeabilized, and stained with IL-13PE, 
IL-4 BV605, and IL-5 BV421. For human experiments, 
PBMCs were stained with Lin BV510 (CD19+, CD56+, 
CD3+, CD20+, CD16+, CD11c+, CD11b+, CD5+, TCRα/
β+, and CD14+), PD-1 APC-Cy7 (clone EH12.2H7) or 
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PD-1 Pe-Cy7 (clone :J10S), GATA3 efluor 660, KLRG1 
PerCPefluor710 (clone 13F12F2), CD45 FITC (clone 
2D1) or CD45 PeCy7 (clone H130), IL13 FITC (clone: 
JES10-SA2), IL5 BV421, and ST2 APC (R&D systems). ILCs 
were detected using the following gating strategy. First cells 
were gated as Lin−CD45+Thy1+, and then ILCs were defined 
as Lin−CD45+Thy1+ CD25+CD127+. ILC-2s were defined as 
Lin−CD45+Thy1+ CD25+CD127+ST2+KLRG1+. In human 
cells, ILC-2s were defined as Lin−CD45+CD127+GATA3+. 
Cells were analyzed using LSR II flow cytometer with FAC 
SDiva software (BD) and analysis was performed with FlowJo 
10.1 software (Tree Star).
In vivo ILc-2 cell stimulation assays
WT or Pdcd1−/− mice were treated with rmIL-33 (R&D 
Systems; 200 ng/mice) or PBS for 3 d, and then lungs were 
isolated for ILC-2 characterization and functional phos-
pho STAT-5 phosphorylation assays. In certain experiments, 
Rag1−/− mice were treated with either αPD-1 antibody 
(BioXcell; clone RMP1-14; 250 µg/mice/d) or mouse IgG2a 
isotype control. After antibody treatment, mice were treated 
with rm-IL-33 or PBS, and then lungs were isolated for 
ILC-2 characterization. For human into murine experiments, 
PBMCs were injected into NSG mice (4 million/mouse), 
followed by i.p injection of rh-IL-2 (500 ng/mouse/d), 
rh-IL-7 (500 ng/mouse/d), and rh-IL-33 (200 ng/mouse/d). 
Certain cohorts were treated with mouse isotype control 
(250 µg/mouse/day) and DMSO Vehicle or with αPD-1 (250 
µg/mouse/d) and Tofacitinib (15 mg/kg/d/mouse) for 3 d. 
Lungs were harvested at day 5 after adoptive transfer, and then 
human ILC-2 numbers and function were evaluated.
StAt5 phosphorylation assays
For STAT-5 phosphorylation assays, WT and Pdcd1−/−mice 
were treated with either PBS or rmIL-33 once, and then 
lungs were isolated the next day. ILC-2s were stimulated with 
IL-2 (100 IU) for 15 min, and then cells were stained for 
p-STAT5 and analyzed by flow cytometry. For PD-1 signal-
ing assays, WT and Pdcd1−/− mice were treated with either 
PBS or rmIL-33 for 3 d, and then lungs were isolated. ILC-2s 
were stimulated with IL-2 (100 IU) alone or IL-2 plus plate-
coated PDL-1-Fc chimera (5 µg/ml) for 15 min, and then 
stained with p-STAT5 antibody. For PDL-1-Fc chimera 
coating, PDL-1-Fc was resuspended in PBS (5 µg/ml), and 
then added to wells in a 24-well plate. The plate was then 
incubated for 3 h at 37°C and then washed three times with 
PBS and then used for cell culture. In a second set of experi-
ments, WT ILC-2 cells were treated with rhIL-2 (40 ng/ml), 
rmIL-7 (40 ng/ml), and rmIL-33 (40 ng/ml). In addition, 
cohorts were treated with either isotype control antibody (10 
µg/ml) or αPD-1 (10 µg/ml), or NSC87877 (SHP1/2 selec-
tive inhibitor; 10 µM resuspended in complete mouse media), 
PDL-1 fc (coated onto plates, and then washed with PBS 
three times before cell culture), or PDL1 fc plus NSC87877 
for 24 h. ILC-2s were then restimulated with IL-2 for 15 min, 
and then subjected to p-STAT5 flow cytometry. For nuclear 
analysis of STAT5a/b, ILC-2s were stimulated for 72 h under 
similar conditions, and then restimulated with IL-2 for 15 
min. Nuclear lysates were prepared according to the manu-
facturer’s instructions (Abcam), and then subjected to tran-
scription factor ELI SA-based assay (Abcam). Similar culture 
methodology was used for detecting human nuclear STAT5 
activity in human ILC-2s. For in vivo STAT5 inhibition ex-
periments, WT or Pdcd1−/− mice were treated with rmIL-33 
plus DMSO or rmIL-33 plus Tofacitinib (15 mg/kg/day) i.p 
for 3 d. Lungs were evaluated for KLRG1+ILC-2 cell number 
and function after treatment.
n. brasiliensis infection
Mice were given subcutaneous injection of 300 third-stage N. 
brasiliensis larvae (provided by J.F. Urban Jr., US Department 
of Agriculture) and cell transfer was performed on the same 
day if required. Mouse feces were collected from each individ-
ual mouse on day 7–9 after infection, and eggs were counted. 
Worm burden in small intestines was measured on day 14.
Proliferation assays
For cell trace violet proliferation assays, murine ILC-2s and 
human ILC-2s were stained with cell trace violet in serum- 
free media as per manufacturer’s instructions. For murine 
cultures, ILC-2s were stimulated with rhIL-2 (40 ng/ml), 
rmIL-7 (40 ng/ml), and rmIL-33 (40 ng/ml), or rmIL-25 (40 
ng/ml), or TSLP (40 ng/ml), and cultured for 72 h in cell cul-
ture media (RPMI, supplemented with 10% FCS, glutamine 
[2 mM], nonessential amino acids [0.1 mM], 2-mercaptoeth-
anol [50 µM], sodium pyruvate [1 mM], penicillin and strep-
tomycin [100 U/ml]), and then proliferation was measured 
by flow cytometry. Human ILC-2s were expanded in the 
presence of rhIL-2 (100 IU), rhIL-7 (40 ng/ml). Certain co-
horts were treated with αPD-1 (20 µg/ml) or isotype control 
(20 µg/ml) alone with either Vehicle (DMSO) or Tofacitinib 
(0.3 µM). Where indicated, rhIL-33 (40 ng/ml) or rhIL-25 
(40 ng/ml), or rhTSLP (40 ng/ml) or rhIL-4 (40 ng/ml), was 
added to the cultures. Cells were expanded for 5 d, and then 
proliferation was measured by flow cytometry.
Microarray
For microarray analysis, flow sorted ILC-2s were pelleted, 
and then resuspended in TRIzol and shipped to Central Bio-
technology Services (CBS; Cardiff University, Cardiff, Wales, 
UK). Total RNA extraction and microarray experiment was 
performed by the CBS. In brief, total RNA was isolated, and 
RNA quality was checked on Agilent Bioanalyzer. All sam-
ples used for microarray analysis have high quality score (RIN 
> 9). RNA was reverse transcribed and amplified, and sense 
strand cDNA was fragmented and labeled using Affymetrix 
WT Pico terminal labeling kit. Three replicates (each repli-
cate was from five mice) of each group were hybridized to 
Affymetrix mouse Gene ST 2.0 GeneChip in Affymetrix hy-
bridization oven at 45°C, 60 rpm for 16 h. Washing and stain-
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ing were performed on Affymetrix Fluidics Station 450 and 
scanned on Affymetrix GeneChip scanner 3000. Data were 
collected using Affymetrix AGCC software. The data dis-
cussed in this publication have been deposited in NCBI Gene 
Expression Omnibus (GEO) and are accessible under GEO 
accession no. GSE94609. The R/Bioconductor package oligo 
(Carvalho and Irizarry, 2010) was used for preprocessing and 
normalization of the microarray data using RMA algorithm 
(Irizarry et al., 2003). The normalized expression values are 
log2-scaled, and probes were annotated (MacDonald, 2016). 
After excluding genes with low variance across arrays (<50% 
quantile) using genefilter (Bourgon et al., 2010) or without 
gene annotation, differentially expressed genes were identi-
fied as those with at least twofold differences and with FDR 
< 0.15 using limma (Ritchie et al., 2015). Gene Ontology 
enrichment analysis for up-regulated genes was conducted 
using DAV ID bioinformatics resources (Huang et al., 2009). 
The GSEA software (Subramanian et al., 2005) was used for 
gene set enrichment analysis. The gene expression data were 
compared against the curated Immunological Signatures gene 
set (C7.all.v5.2), with the permutation type set as gene_set.
Statistics
Results are expressed as mean with error bars showing ±SEM 
unless otherwise indicated. Statistical significance was deter-
mined for normally distributed data by using a Student’s t 
test or a one-way ANO VA, followed by appropriate multi-
ple comparison tests. All analysis were performed using Prism 
7.0 (GraphPad Software), and differences were considered 
significant when P ≤ 0.05.
online supplemental material
Fig. S1 shows gating strategy for ILC analysis, cytokine 
receptor expression, and PD-1 expression during homeo-
stasis and cytokine stimulation on ILC-2s. Fig. S2 shows 
the proliferative effect of ILC-2 driving cytokines on WT 
and Pdcd1−/− ILC-2s. Effect of in vivo IL-25 administra-
tion on ILC-2 cell numbers in WT and Pdcd1−/− ILC-2s, 
and the importance of PD-1 and STAT5 signaling in WT 
and Pdcd1−/− ILC-2s. Fig. S3 demonstrates the changes 
in ILC-2 numbers during helminth infection in WT and 
Pdcd1−/− mice. Fig. S4 demonstrates the significance of 
PD-1 in human KLRG1+ ILC-2s.
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